The increasing complexity of biological research and the push for miniaturized, point-of-care diagnostic devices necessitate fluorescent materials that perform reliably under diverse conditions. Furthermore, the drive for more sustainable and cost-effective solutions in both medical and industrial applications is accelerating the search for materials that reduce reagent consumption and simplify operational protocols, making robust, water-soluble, and stable fluorescent probes critically important.
Provides stable luminescence in aqueous environments, independent of pH or polarity, enabling reliable data acquisition across diverse biological and solution systems.
Maintains high quantum efficiency without concentration quenching, allowing high-sensitivity and high-concentration use, optimizing reagent quantity and improving diagnostic accuracy and cost efficiency.
Achieves superior luminescence properties with a molecular size equivalent to the versatile BODIPY dye, facilitating easy integration into existing fluorescent probes and diagnostic kits for rapid product commercialization.
This patent protects novel compounds featuring a sulfonyl aniline backbone, defined by specific structural formulas. The claims, though concise, encompass a broad range of substituent possibilities, allowing for the development of various derivatives. The patent's robustness, having overcome examiner objections and been granted with strong legal representation, suggests a clear and difficult-to-invalidate scope, providing a stable foundation for business development and long-term competitive advantage.
While protecting the core sulfonyl aniline backbone, this patent leaves white space in specific device integration, advanced biosensor architectures, and novel light-emitting device designs. Licensees could develop complementary IP in areas like microfluidic diagnostic platforms or multi-modal imaging systems that leverage these materials without infringing the core chemical claims.
In high-sensitivity diagnostic reagent development, this technology's stability and high efficiency could reduce reagent usage by 20% compared to conventional fluorescent reagents, saving ~$50K/year (AI est.) based on an annual reagent cost of ~$350K (AI est.). Additionally, if the technology's superior properties shorten development time by an average of 6 months, a new product with ~$50K/month (AI est.) in sales could launch 6 months earlier, leading to a total economic impact of ~$750K/year (AI est.).
X: High Functionality & Versatility
Y: Cost Efficiency